Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis

Thyroid ◽  
2007 ◽  
Vol 17 (12) ◽  
pp. 1277-1288 ◽  
Author(s):  
Shoba Subramanian ◽  
David P. Goldstein ◽  
Luciana Parlea ◽  
Lehana Thabane ◽  
Shereen Ezzat ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Cancer Survivors ◽  
Meta Analysis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Malignancy Risk

scholarly journals Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis

Thyroid ◽  
2009 ◽  
Vol 19 (5) ◽  
pp. 451-457 ◽  
Author(s):  
Anna M. Sawka ◽  
Lehana Thabane ◽  
Luciana Parlea ◽  
Irada Ibrahim-Zada ◽  
Richard W. Tsang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Radioactive Iodine ◽  
Meta Analysis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Malignancy Risk ◽  
Iodine Treatment

scholarly journals Second primary malignancy risk after radiotherapy in rectal cancer survivors

2018 ◽  
Vol 24 (40) ◽  
pp. 4586-4595 ◽  
Author(s):  
Ti-Hao Wang ◽  
Chia-Jen Liu ◽  
Tze-Fan Chao ◽  
Tzeng-Ji Chen ◽  
Yu-Wen Hu
Keyword(s):  
Rectal Cancer ◽  
Cancer Survivors ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Malignancy Risk

Occurrence of second primary malignancy in medullary thyroid cancer (MTC) patients

2019 ◽  
Author(s):  
George Simeakis ◽  
Katerina Saltiki ◽  
Evangelia Zapanti ◽  
Evanthia Kassis ◽  
Maria Alevizaki
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Medullary Thyroid

Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis

2019 ◽  
Vol 13 (2) ◽  
pp. 231-243 ◽  
Author(s):  
Omar Saeed ◽  
Lori J. Bernstein ◽  
Rouhi Fazelzad ◽  
Mary Samuels ◽  
Lynn A. Burmeister ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Cancer Survivors ◽  
Cognitive Functioning ◽  
Meta Analysis

Prognosis of lung cancer as a second primary malignancy among cancer survivors: A population-based cohort study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21005-e21005
Author(s):  
Lei Deng ◽  
Zhengrui Xiao ◽  
Changchuan Jiang ◽  
Qian Wang ◽  
Haiying Cheng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Cancer Survivors ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

The risk of second primary cancers in clear cell and papillary renal cancer.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 446-446 ◽  
Author(s):  
Muhammad Saad Hamid ◽  
Raji Shameem ◽  
Rishi Jain ◽  
Kevin M. Sullivan
Keyword(s):  
Thyroid Cancer ◽  
Solid Tumors ◽  
Clear Cell ◽  
Latency Period ◽  
Initial Diagnosis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Second Primary Cancers ◽  
Increased Risk

446 Background: Renal cell carcinoma (RCC) survivors have an increased risk of developing second primary cancers. We sought to determine the role of RCC tumor histology for the risk of developing second primary solid tumors. Methods: The Surveillance Epidemiology and End Results (SEER) database was used to detect RCC cases diagnosed up to 12/31/2011. The Standardized Incidence Ratio (SIR) was calculated as the ratio of observed to expected cases of second primary malignancy based on incidence data in the general United States population. The two most common RCC histological subtypes were included; clear cell and papillary. The latency exclusion period from the date of diagnosis was 60 months. We investigated for the effect of latency period after initial diagnosis (5-10 years and >10 years) that may increase the risk for a second primary cancer. Results: A total of 2,669 patients with an initial diagnosis of RCC (clear cell: 2,368, papillary: 301) that developed second primary cancers were included in our analysis. There was a significantly increased risk of thyroid cancer (SIR: 2.30, p<0.05), prostate cancer (SIR: 1.12, p<0.05) and “all solid tumors” (SIR: 1.14, p<0.05) in clear cell RCC cases. Regarding latency period, thyroid cancer (SIR: 2.87, p<0.05) risk was increased in the 5-10 years latency period, but not in the >10 years latency period. Overall, in patients diagnosed with papillary RCC, tumors of the prostate (SIR: 1.30, p<0.05), lung (SIR: 1.78, p<0.05) and pancreas (SIR: 2.70, p<0.05) were increased. Exclusively in the 5-10 years latency period, the risk for developing lung cancer (SIR: 1.90, p<0.05) was significant. Conclusions: RCC histology may impact the risk for developing specific second primary solid tumors.

Sign in / Sign up

Export Citation Format

Share Document